MEI Pharma Inc (NASDAQ:MEIP)
| 6.17 Delayed Data As of Nov 28 |  -0.47 / -7.11%Today’s Change | 4.00 Today|||52-Week Range 8.60 | +26.64% Year-to-Date |
Latest MEIP News | Press Releases
| AstraZeneca's (AZN) Capivasertib Gets FDA Nod for Breast Cancer Nov 17 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 6.61 |
| Today’s open | 6.50 |
| Day’s range | 5.98 - 6.53 |
| Volume | 89,544 |
| Average volume (3 months) | 49,869 |
| Market cap | $41.4M |
Data as of 3:59pm ET, 11/28/2023
Growth & Valuation
| Earnings growth (last year) | +45.39% |
| Earnings growth (this year) | -32.98% |
| Earnings growth (next 5 years) | -0.25% |
| Revenue growth (last year) | +19.95% |
| P/E ratio | 1.0 |
| Price/Sales | 0.90 |
| Price/Book | 1.68 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| FBIOPFortress Biotech Inc | +0.68 | +6.08% |
| SCTLSocietal CDMO Inc | -0.00 | -0.47% |
| GSGTFGensight Biologics S... | 0.00 | 0.00% |
| NERVMinerva Neuroscience... | +0.49 | +9.59% |
Data as of 3:59pm ET, 11/28/2023
Financials
| Next reporting date | February 8, 2024 |
| EPS forecast (this quarter) | -$4.44 |
| Annual revenue (last year) | $48.8M |
| Annual profit (last year) | -$31.8M |
| Net profit margin | -65.22% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters San Diego, California |
Forecasts
